

Program Description

Building on last year's success, the 2nd Parathyroid Summit will review global advances in the diagnosis and management of hypoparathyroidism (HypoPT) and develop a review paper summarizing the advances in research and new therapeutic options in the management of hypoparathyroidism. Recognized international authorities in parathyroid disease as well as leaders in general endocrinology will present new research.

Groundbreaking scientific discoveries in medicine are advancing bench to bedside research in hypoparathyroidism. These basic research breakthroughs over the last decade have translated into several registration clinical trials. The armamentarium of drugs available for the cure of hypoparathyroidism is rapidly increasing making it possible to fill the gap in medical interventions in this important and for long neglected disorder of mineral metabolism.

The 2025 Summit on Hypoparathyroidism will be fully devoted to the novel discoveries of basic research in hypoparathyroidism that have brought or are going to bring novel therapies for hypoparathyroid patients. Scientists from the academy and the industries will present the development of new therapies in hypoparathyroidism.

Faculty

- Summit Chairs: Maria Luisa Brandi, Aliya A. Khan
- Scientific Planning Committee: Wenhan Chang, Michael T. Collins, Arthur Conigrave, Thomas J. Gardella, Harald Jueppner, Noriko Makita, Kelly Roszko

Learning Objectives

At the end of the 2025 Parathyroid Summit, participants will be able to:

- Identify unmet needs in the diagnosis and medical management of hypoparathyroidism
- Outline recent insights in Calcium-Sensor Receptor (CaSR) activation and the potential of calcilytics
- Discuss advances in PTH basic research and corresponding clinical implications
- Describe advances in cell therapies research and corresponding clinical implications

Preliminary Program

I. INTRODUCTION

Moderators:

- a. The History of the Summit and Future Projections
- b. Why Focus on Basic Research?

II. BACKGROUND

Moderators:

- a. Diagnosis of Hypoparathyroidism: Unmet Needs -
- b. Medical Management of Hypoparathyroidism: Unmet Needs
- c. Quality of Life: Unmet Needs

III. CaSR AS A TARGET

Moderators:

- a. Development of Calcilytics
- b. Promiscuous G protein activation by the CaSR
- c. Activating CaSR Variant with Biased Signaling and Proposed Role in Galpha11 activation
- d. Update on Encaleret in ADH1 and Postsurgical Hypoparathyroidism
- e. Potential New Calcilytics

IV. PTH PEPTIDES

Moderators:

- a. PTH1-34
- b. PTH1-84
- c. Palopegteriparatide
Basic Research
Clinical Development
- d. Once weekly Canvuparatide
Basic Research
Clinical Development

V. PTHR1 AS A TARGET

Moderators:

- a. Eneboparatide
Basic Research
Clinical Development
- b. Small Agonists
Basic Research
Clinical Development-

VI. CELL THERAPIES

VII. PANEL DISCUSSION: Physician and patient expectations for new drugs in market or upcoming

Accreditation

The 2nd Parathyroid Summit will be an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada, as approved by The Canadian Society of Endocrinology and Metabolism.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™.

Live educational activities recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists (UEMS) eligible for ECMEC®.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the Qatar Council for Healthcare Practitioners, healthcare practitioners participating in the QCHP CME/CPD program may record MOC Section 1 as QCHP Category 1 credits.